By coating tiny gel beads with lung-derived stem cells and then allowing them to self-assemble into the shapes of the air sacs found in human lungs, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have succeeded in creating three-dimensional lung “organoids.” The laboratory-grown lung-like tissue can be used to study diseases including idiopathic pulmonary fibrosis, which has traditionally been difficult to study using conventional methods.
“While we haven’t built a fully functional lung, we’ve been able to take lung cells and place them in the correct geometrical spacing and pattern to mimic a human lung,” said Dr. Brigitte Gomperts, an associate professor of pediatric hematology/oncology and the study’s lead author.
Idiopathic pulmonary fibrosis is a chronic lung disease characterized by scarring of the lungs. The scarring makes the lungs thick and stiff, which over time results in progressively worsening shortness of breath and lack of oxygen to the brain and vital organs. After diagnosis, most people with the disease live about three to five years. Though researchers do not know what causes idiopathic pulmonary fibrosis in all cases, for a small percentage of people it runs in their families. Additionally, cigarette smoking and exposure to certain types of dust can increase the risk of developing the disease.
To study the effect of genetic mutations or drugs on lung cells, researchers have previously relied on two-dimensional cultures of the cells. But when they take cells from people with idiopathic pulmonary fibrosis and grow them on these flat cultures, the cells appear healthy. “Scientists have really not been able to model lung scarring in a dish,” said Gomperts, who is a member of the UCLA Broad Stem Cell Research Center. The inability to model idiopathic pulmonary fibrosis in the laboratory makes it difficult to study the biology of the disease and design possible treatments.
Gomperts and her colleagues started with stem cells created using cells from adult lungs. They used those cells to coat sticky hydrogel beads, and then they partitioned these beads into small wells, each only 7 millimeters across. Inside each well, the lung cells grew around the beads, which linked them and formed an evenly distributed three-dimensional pattern. To show that these tiny organoids mimicked the structure of actual lungs, the researchers compared the lab-grown tissues with real sections of human lung.
“The technique is very simple,” said Dan Wilkinson, a graduate student in the department of materials science and engineering and the paper’s first author. “We can make thousands of reproducible pieces of tissue that resemble lung and contain patient-specific cells.”
Moreover, when Wilkinson and Gomperts added certain molecular factors to the 3-D cultures, the lungs developed scars similar to those seen in the lungs of people who have idiopathic pulmonary fibrosis, something that could not be accomplished using two-dimensional cultures of these cells.
Using the new lung organoids, researchers will be able to study the biological underpinnings of lung diseases including idiopathic pulmonary fibrosis, and also test possible treatments for the diseases. To study an individual’s disease, or what drugs might work best in their case, clinicians could collect cells from the person, turn them into stem cells, coax those stem cells to differentiate into lung cells, then use those cells in 3-D cultures. Because it’s so easy to create many tiny organoids at once, researchers could screen the effect of many drugs. “This is the basis for precision medicine and personalized treatments,” Gomperts said.
The Latest on: Precision medicine
via Google News
The Latest on: Precision medicine
- LabCorp’s new assay expands its precision medicine portfolio on February 19, 2019 at 10:01 am
BURLINGTON – LabCorp is offering a new assay to help doctors monitor drug responses in patients taking Certolizumab, a biologic therapy for certain inflammatory diseases such as rheumatoid arthritis a... […]
- LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio on February 19, 2019 at 5:14 am
LabCorp® LH, +2.32% a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio ... […]
- Precision Medicine Market Analysis and Growth to 2025: By Key Companies Johnson & Johnson, IBM, GE Healthcare, Illumina on February 19, 2019 at 4:36 am
QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods ... […]
- Precision Medicine Market 2019 to Grow Radically at 12.48% CAGR | Size, Growth, Trends and Forecast by 2022 on February 19, 2019 at 4:32 am
Feb 19, 2019 (Heraldkeeper via COMTEX) -- The major market driving factor for precision medicine are patient's involvement in personal healthcare, integration of wireless technologies with portable he... […]
- The Challenge of Precision Medicine in mCRPC on February 18, 2019 at 6:20 am
Over the past decade, we have used the terms personalized medicine and precision medicine interchangeably. For the most part, patient care has always been personalized. Yes, some want to make it more ... […]
- Global Precision Medicine Market is Register CAGR 12.71% Growth during 2018-2023 on February 18, 2019 at 4:10 am
A recent study on Precision Medicine Market by KD Market Insights provides analysis of various factors that can affect the market share. The titled report " Precision Medicine Market: Market Size, Tre... […]
- Viewpoint: It’s time for a debate on precision medicine and its failed promises on February 14, 2019 at 5:32 am
Although some niche applications have been found for precision medicine, and gene therapy is now becoming a reality for a few rare diseases, the effects on public health are minuscule while the ... […]
- How Machine Learning Is Crafting Precision Medicine on February 11, 2019 at 10:07 am
edicine has become more and more individualized since the days of leeches and humors, but in the last 15 years, an explosion of patient data in the form of genetic information and electronic health re... […]
- Precision medicine’s rosy predictions haven’t come true. We need fewer promises and more debate on February 7, 2019 at 1:45 am
Twenty years ago, Dr. Francis Collins, who was then director of the National Center for Human Genome Research, made rosy predictions in his Shattuck Lecture about the health benefits sure to flow from ... […]
via Bing News